WCLC 2025 - Posters & ePosters-EP.07.49 Neoadjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series

EP.07.49 Neoadjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series

Pdf Summary

This case series from Peking University Cancer Hospital reports on the use of sunvozertinib, a potent oral EGFR tyrosine kinase inhibitor (EGFR-TKI), as neoadjuvant therapy in three early-stage non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. Sunvozertinib is approved for advanced NSCLC with this mutation and has demonstrated a 61% response rate in advanced cases, but its neoadjuvant utility has been less studied.<br /><br />The retrospective analysis included three patients aged 54 to 78 years, all diagnosed with lung adenocarcinoma and staged IIIB, IIIA, and IIB, respectively. Molecular diagnosis was made by next-generation sequencing or PCR. Patients received sunvozertinib doses of 150-300 mg daily for 3 to 6 months before surgery. All three achieved a clear partial response per RECIST v1.1 criteria and successfully underwent radical surgery. Safety was favorable, with only mild (grade 1) diarrhea reported in one patient and no new safety concerns observed.<br /><br />The findings indicate encouraging antitumor activity and an acceptable safety profile of sunvozertinib as neoadjuvant therapy in early-stage EGFR exon 20 insertion mutant NSCLC, providing clinical benefit by shrinking tumors before surgical resection. The authors suggest that prospective studies with larger sample sizes are needed to confirm these results and further evaluate sunvozertinib's role in early-stage NSCLC treatment.<br /><br />In summary, this preliminary real-world evidence supports sunvozertinib’s potential as an effective and safe neoadjuvant approach in early-stage NSCLC patients harboring EGFR exon 20 insertion mutations, expanding therapeutic strategies beyond advanced disease settings.

Asset Subtitle

Jinfeng Chen

Meta Tag

Speaker Jinfeng Chen

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

sunvozertinib

EGFR tyrosine kinase inhibitor

EGFR exon 20 insertion mutation

non-small cell lung cancer

NSCLC

neoadjuvant therapy

lung adenocarcinoma

partial response

RECIST v1.1

radical surgery